anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Various immunologically active proteins from  Borrelia burgdorferi  have been prepared by genetic manipulation in microorganisms. To do this, the specific DNA sequences were selected from a  B. burgdorferi  gene bank using suitable screening methods, or were prepared directly by DNA amplification using selected hybridization probes, and were placed under the control of inducible promoters such as, for example, the lac promoter. It has been possible, owing to description of efficient purification methods for the expressed antigens, to provide the proteins in a suitable way. These proteins can be used to produce specific and sensitive diagnostic assay kits. The specific combination of the immunologically active proteins makes precise diagnosis possible. Furthermore, monoclonal antibodies have been generated and are used as reagents for detecting pathogens directly in test samples or after cultivation. The  Borrelia burgdorferi —specific DNA sequences can be employed for direct detection of the pathogen in patients&#39; samples (for example by means of the PCR reaction).
FIELD: medicine.SUBSTANCE: invention can be used for treating recurrent acute myeloid leukaemia (AML) following the transplantation of allogenic haemopoietic stem cells. That is ensured by chemotherapy followed by administering (taking into account donor&#39;s leukocyte chimerism) donor&#39;s bone marrow lymphocytes in a combination with interleukin 2 (IL-2). The chemotherapy is conducted by the intravenous administration of anti-tumour preparations of cytabarine 100 mg/mtwice a day for 7 days and indarubicine 12 mg/m1 time a day within 3 days. With underlying myelotoxic agranulocytosis with a granulocyte count of less than 0.5×10/l, the donor&#39;s bone marrow lymphocytes are transfused is a dose of 1×10CD3+cells/kg of the patient&#39;s body weight that is followed by the intravenous drop-by-drop administration of IL-2 in a dose of 6 mln International Units 1-2 hours later. The 100% absence of the donor&#39;s leukocyte chimerism and any signs of the graft vs. host disease, the following two donor&#39;s lymphocyte transfusions and IL-2 infusions in a dose of 6 mln International Units are performed the first of the two donor&#39;s bone marrow lymphocyte transfusions is performed in a dose of 5×10CD3+cells/kg, and the second one - in a dose of 1×10CD3+cells/kg. The transfusion cycle makes 2-4 weeks. That is followed by therapeutic supporting course of IL-2 administration in a dose of 2 mln International Units a day for 5 days intravenously; the course cycle makes 4-5 weeks with the supporting therapy lasting for 2 years.EFFECT: higher clinical effectiveness of post-transplantation recurrence, achieved long-lasting recurrent remissions, higher overall survival rate in the patients with acute myeloid leukaemia.2 ex
Colloidal solutions of silver in oils, fats, or fatty acids are prepared by introducing silver oxide, hydroxide, carbonate, or other compound capable of forming a soap with oils &amp;c. into the oil fat, or fatty acid at 200-300 DEG  C. filtering the resulting solution, and passing in hydrogen.  The silver soap formed acts as a protective colloid.  The reduction by hydrogen may be preceded by the addition of an organic reducing agent, preferably oil-soluble such as hydroquinone.  The solutions thus obtained may, by heating with mercury, mercuric oxide, or other mercury compound, form colloidal solutions of silver and mercury.  In examples the precipitate obtained by adding caustic soda to a solution of a silver salt is added to oil, fat, or fatty acid at 200-300 DEG  C. and the solution filtered, when hydroquinone may be added and hydrogen is led in. Further examples show the addition of mercury and mercuric oxide to solutions of silver in olive oil and lard respectively. Specification 12982/13 is referred to.ALSO:In a process for preparing colloidal solutions of silver in oils, fats, or fatty acids by introducing silver oxide, hydroxide, carbonate, or other compound capable of forming a soap with oils &amp;c. at a high temperature, into the oil, fat, or fatty acid at 200 DEG -300 DEG  C., filtering the resulting solution, and passing in hydrogen, silver soap is formed and acts as the protective colloid.  The reduction by hydrogen may be preceded by the addition of another reducing agent preferably oil-soluble such as hydroquinone.  Specification 12982/13, [Class 1 (i), Chemical processes &amp;c.], is referred to.
An improved barrier or drug delivery system which is highly adherent to the surface to which it is applied is disclosed, along with methods for making the barrier. In the preferred embodiment, tissue is stained with a photoinitiator, then the polymer solution or gel having added thereto a defined amount of the same or a different photoinitator is applied to the tissue. On exposure to light, the resulting system polymerizes at the surface, giving excellent adherence, and also forms a gel in the rest of the applied volume. Thus a gel barrier of arbitrary thickness can be applied to a surface while maintaining high adherence at the interface. This process is referred to herein as &#34;priming&#34;. The polymerizable barrier materials are highly useful for sealing tissue surfaces and junctions against leaks of fluids. In another embodiment, &#34;priming&#34; can be used to reliably adhere preformed barriers to tissue or other surfaces, or to adhere tissue surfaces to each other. A first surface and a barrier, or another surface, are prestained with initiator, and a thin layer of gellable monomer containing initiator is placed between them. Strong adhesion is obtained between the two surfaces on gelation of the monomer. In a similar fashion, tissue surfaces can be adhered to each other in repair of wounds and formation of anastomoses. Methods for use of non-photochemical systems and combined chemical/photochemical systems are described.
A cosmetic product kit and method is provided for removing keratotic plugs from pores on various areas of the face. Included within the kit are at least two different types of strips each with differing geometry for placement along specific portions of a person&#39;s facial anatomy. For instance, there may be specific strips for the forehead, nose and chin/cheeks. These strips are flexible substrate sheets upon which an adhesive polymer is deposited. The method involves wetting the strip to tackify the polymer and activate the adhesivity. The strips are applied to the relevant area of the face, allowed to air dry and peeled away thereby removing the keratotic plugs from the pores.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method to therapeutically modulate immune functions of autoimmune diseases and other disorders in immune systems in a mammal.  &lt;P&gt;SOLUTION: The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell (e.g., an antigen-presenting cell) is disclosed. Such inhibition is useful for treatment of diseases including the various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-gamma by lymphocytes or other immune cells in the mammal. Inhibition of IFN-gamma is useful for treatment of inflammatory diseases or disorders (e.g., inflammatory bowel disease).  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To provide a sustained release article capable of stably releasing a polypeptide over a long period of time by employing a high mol.wt. polymer as a carrier and simultaneously changing the polymer into a porous structure. CONSTITUTION:A sustained release article comprises a polypeptide contained in a polymer (e.g. L-lactic acid homopolymer, L-lactic acid-glycolic acid copolymer) which has a weight-average mol.wt. of &gt;=50000, preferably 70000-200000, and which is hydrolyzed in a living body or when contacting with water, the polymer having a porous structure with a porosity of 20-70%. Examples of the polypeptide include human fibronectin, cells containing the human fibronectin, a functional domain polypeptide exhibiting an activity to bond to collagen, heparin, etc., and a polypeptide containing an amino acid sequence of formula: arginine-glycine-asparagine. An aqueous solution of the polypeptide is emulsified in a solution of the polymer, and the produced W/O type emulsion is added to water to form a W/O/W type emulsion, which is subjected to a drying method in water to remove the solvent in the oil layer for providing the sustained release article.
The thioester of N-acetyl-cysteine with p-isobutylphenyl- propionic acid shows simultaneous anti-inflammatory and mucolytic activity. It is prepared by the reaction of a reactive derivative of p-isobutylphenylpropionic acid and N-acetyl-cysteine at low temperature in a polar solvent. Salts with organic and inorganic bases, with basic amino acids and with basic antibiotics which have a macromolecular structure are stable and generally soluble in water, as a result of which the active ingredient according to the invention can be formulated for oral, parenteral, rectal and topical administration. This invention relates to a thioester of N-acetyl- cysteine propionyl glycine with p-isobutylphenylpropionic acid, which has the formula: &lt;IMAGE&gt; and which has useful anti-inflammatory and mucolytic properties, and its pharmacologically acceptable non- toxic salts. The anti-inflammatory activity of p- isobutylphenylpropionic acid is known, and the disadvantages from the point of view of its therapeutic use are also known. The compound according to the invention, as such or converted into a salt with organic bases containing alkaline or alkaline earth ions, or with basic amino acids such as arginine and lysine, or with the nuclei of basic antibiotics such as erythromycin and propionyl erythromycin, demonstrate useful properties as they have anti-inflammatory and mucolytic activity at the same time. This invention also relates to processes for the preparation of the subject compound which are characterised in that a p-isobutylphenylpropionic acid halide and a derivative of N-acetyl-cysteine are caused to react in a medium which has an alkaline pH containing a polar solvent, preferably water or mixtures of water and dioxan, at low temperature, giving rise to a low melting point thioester which is an odourless pale yellow oil at ambient temperature. The reaction product as such is free from impurities and is used in the reaction to form the salt with the various bases mentioned above in order to obtain the corresponding salts, which are stable, water-soluble and easy to use in the pharmaceutical field.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide silicone fibers and silicone fabrics for use as medical fibers and fabrics, these application, and methods for their production.  &lt;P&gt;SOLUTION: The fiber or fabric comprising silicone for use as the medical fiber or fabric. The silicon can be biocompatible, bioactive or resorbable material and may also be able to act as an electrical conductor. In addition, porous silicon may be used as a slow release means for example for drugs or fragrances, or as a collector for example for sweat. Novel fibers, fabrics and methods of preparation of these are also described and claimed.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Low concentrations of the protein kinase C activators, bryostatins 1 and 2 synergized with rBSF-1 are useful in triggering differentiation (granule enzyme expression) and CTL development in naive, resting lymph node T-cells. Bryostatin greatly enhances efficiency of rIL-2 in triggering development of in vivo primed CTL during in vitro incubation, thereby providing evidence for the use of lower concentrations of rIL-2 for in vivo tumor rejection. Both bryostatin 1 and 2, trigger cytotoxicity of CTL clones against Ag-non-bearing target cells and inhibit CTL cytotoxicity against Ag-specific target cells. Bryostatin 1 and 2 synergize with Ca&lt;+&gt;&lt;+&gt; ionophores in triggering the exocytosis of cytolytic granules from CTL at very low concentrations. Because of the lack of tumor promoting activity in the bryostatins, they are useful per se as immunomodulating drugs and as potentiators for rIL-2 in adoptive immunotherapy. &lt;CHEM&gt; y
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an infection-protecting agent for inhibiting the invasion of pathogenic bacteria participating in the crises and serious states of colds or the like and for inhibiting the adhesion of the pathogenic bacteria to epithelial cells to prevent the infections of such as upper and lower respiratory tract infections.  &lt;P&gt;SOLUTION: This infection-protecting agent comprises amylase. A bacterium adhesion inhibitor comprises amylase. A composition for oral cavities contains amylase. Thereby, the adhesion of the bacteria to the epithelial cells can be inhibited to protect the infection of the upper and lower respiratory tracts with the bacteria.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for reconstituting an animal embryo useful for producing a transgenic animal and a non-transgenic animal having a high genetic value.  &lt;P&gt;SOLUTION: In this method, a nucleus derived from a donor cell in a quiescent state is transferred into a suitable recipient cell. The donor cell exists in the quiescent state, from a viewpoint that the cell exits from a growth and division cycle on a G1 stage and remains in a G0 state. Nuclear transfer is conducted by cell fusion. Further, one or more animals are produced from the embryo thus reconstituted.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
A document is created and digitally signed using an author&#39;s private key. The signed document is provided to an electronic notary who notarizes (provides a time/date stamp and signs the time/date stamp using the notary&#39;s private key) the authors signed document. A reviewer requests and verifies the origin and integrity of the authors signed document using the author&#39;s public key. As the reviewer examines the documentary, a log is automatically created. The review log and reviewed document are digitally signed using the reviewer&#39;s private key and the signed reviewed document is provided to an electronic notary who notarizes the signed reviewed document. An auditor requests the reviewed document. The auditor verifies the origin and integrity of the document using the notary&#39;s public key. The auditor audits the signed review document.
1429184 Anti-inflammatory steroid crystallisates ALLEN &amp; HANBURYS Ltd 18 April 1973 [20 April 1972] 18421/72 Heading C2U [Also in Division C4] The invention comprises an anti-inflammatory steroid in the form of a crystalline solvate with a halobydrocarbon or such a crystalline material from which part or all of the halohydrocarbon has been removed, the particle size of substantially all of the steroid material being such as to permit inhalation into the human bronchial system when dispersed as an aerosol, e.g. 2- 20 Á. Several specific steroids of the pregna-1,4- diene-3,20-dione series are mentioned. Specified halohydrocarbons are CH 2 Cl 2 , CHCl 3 , CFCl 3 , CCl 2 F 2 , C 2 Cl 2 F 4 , C 2 Cl 3 F 3  and C 2 ClF 5 . Preparation.-The initial unsolvated steroid is first contacted with the halohydrocarbon. Simple suspension with concurrent comminution yields an inventive product. Alternatively the halohydrocarbon is mixed with a solution of the steroid in a conventional steroid solvent (e.g. MeOH, EtOH, Pr&lt;SP&gt;i&lt;/SP&gt;OH, HCHO, CH 2 Cl 2 , acetone) and the resulting mixture is either crystallized at low temperature, e.g. -29 to -40 C., or distilled until the conventional solvent has been removed whereupon the solvate crystallizes. The optional removal of the halohydrocarbon from the solvate may be effected by heating at up to 60 C. in a vacuum, and may also take place automatically upon comminution. The latter may be effected ultrasonically or in a ball or fluid energy mill. Anti-inflammatory aerosol compositions comprise a suspension of a product of the invention in an aerosol propellant and a dispersing agent. (The steroid has a modified crystal structure and does not exhibit crystal growth in the propellant.)
The invention relates to a medicine for treating whelk by the use of Chinese herbal medicines as raw materials and a production method thereof. The present method for treating whelk is oral administration of antibiotics, which will imperceptibly increase liver and kidney burden. Photodynamic therapy requires high treatment cost such that consumers can&#39;t afford. Contraceptive drugs have side-effect. Squeezing out acne directly for will lead to scars and aggravate infection. According to whelk pathogenesis, the medicine provided by the invention is prepared by immersing dandelion, barbados aloe and peach blossom in 27-42 weight parts of medical alcohol with the concentration of 50-95%. By the utilization of traditional Chinese medicines, the medicine provided by the invention treats both principal and secondary aspect of whelk. By the adoption of the medicine prepared by the production method, the cure rate of the medicine reaches 100% with no relapse.
PURPOSE: To surely prevent the backflow of medicines and to make it possible to dose the medicine by a simple dosing operation. CONSTITUTION: A capsule holder 2 having a capsule housing hole 5 is provided with a pump part 18 on its inflow side and is provided with a medicines spraying part 22 having two medicine flow passages 27, 27 branched from the capsule housing hole 5 and spraying ports 28, 28 on its outflow side. The medicine spraying part 22 is internally provided with a boring means 32. A backflow preventive part 17 which captures the medicines falling from the capsule in the capsule housing hole 5 and return the medicines to the capsule housing hole 5 side by the air from the pump part 18 at the time of administration is disposed between the capsule housing hole 5 and the pump part 18. Then, the medicines in the capsule are dosed into the patient&#39;s left and right nasal cavities from the respective spraying ports 28 when the capsule is bored with a through-hole by the boring means 32 and the air is supplied from the pump part 18. The backflow of the medicines in the capsule is prevented by the backflow preventive part 17 and, therefore, the need for a valve mechanism is eliminated.
Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administraters to a mammal viral vectors that deliver genes expressing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis. Embodiments of the present invention are directed primarly, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF singaling through its receptor. Pathobiologic phenomena inlcude, but are not limited to, disease entities such as osteoprosis, Alzheimer&#39;s disease, diabetes mellitus (Type 1 and/or Type 2), infectious disease, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.
PURPOSE:To obtain a cosmetic base having excellent affinity for hair and skin, providing a nice feeling in use and a finishing feeling by using a specific low- viscosity cationic starch. CONSTITUTION:A low-viscosity cationic starch obtained by reacting a starch with a compound of formula I or formula II (R1 to R3 are 1-3C alkyl; X&lt;-&gt; is monovalent anion; Hal is halogen) in such a way that the content of nitrogen is 0.2-3wt.% is used as a cosmetic base. Namely the low-viscosity cationic starch is a low-viscosity cationic cosmetic having structure wherein the hydroxyl group of the starch is replaced with residue of formula III, 0.2-3wt.% of nitrogen content and 3-500cps viscosity in 30wt.% aqueous solution at 30 deg.C. The amount of the cosmetic base blended is preferably 0.1-7wt.%. This cosmetic base has excellent affinity for hair and skin, excellent film-forming ability and adsorbability to hair and skin. The cosmetic base has excellent moisture retention, makes hair wet, provides hair with stiff softness and luster and shows durability.
PURPOSE: To provide a new inflammation inhibitor capable of inhibiting endotoxin-inducible cytokine release, containing, as active ingredient, a lactoferrin-derived specific peptide. CONSTITUTION: This inflammation inhibitor contains, as active ingredient, a peptide &lt;=10000 dalton in molecular weight derived from the N-terminal domain of lactoferrin. The peptide, which presents action to inhibit endotoxin-inducible cytokine release from immunocytes (for example, to inhibit interleukin-6 release from human monocytes due to endotoxin stimulation), has effect at concentrations of as low as 0.5-50ppm. Therefore, this inhibitor is useful for preventing and treating harmful effects due to endotoxin such as acute inflammation and septicemia, mediated by cytokine, due to Gram-negative bacteria. The peptide is obtained by hydrolysis of lactoferrin or by conventional peptide synthetic process, and purified. This inhibitor can be used in the form of oral agent, injection, eye drop or spray, or quasi-drug (e.g. mouthwash), cosmetic, food (e.g. chewing gum), etc.
PURPOSE:To prepare beauty wash which can be stored for a long period, and used safely even by a person having sensitive skin, by aging a mixture composed mainly of natural lemon and pure honey at a constant temperature for a definite period. CONSTITUTION:Sliced lemon fruits are immersed in alcohol, and mixed with pure honey and purified water. The mixture is stored in a vessel at a definite temperature of &gt;=42 deg.C, pref. 42-45 deg.C for &gt;=24 hours to obtain the objective beauty wash. The beauty wash has a Brix degree of 18-23 deg.C, a pH value of 3.0-4.0, and a clarity of 10, and can be stored without discoloration and change in smell. The citric acid existing in lemon cures the fatigue of the skin, and the vitamin C decomposes the melanin of the skin. The various components in the honey (e.g. minerals, vitamin B1, B2, etc.) are effective to the nourishing and disinfection of the skin.
The present invention describes chimeric vaccine antigens against the virus that causes classical swine fever (CSFV). Said vaccine antigens are based on viral subunits that are coupled to protein molecules that stimulate not only the cellular but also the humoral immune system. The chimeric antigens may by produced in expression systems that guarantee correct three-dimensional folding of the chimeric molecules that constitute the basis of the present invention. The vaccine compositions that contain said chimeric antigens induce a potent, early immune response in vaccinated pigs, conferring total protection against CSFV. In addition, the resulting vaccine compositions prevent viral transmission from sow to progeny. The chimeric antigens, and also the resulting vaccine compositions, are applicable to the field of animal health as vaccines for preventive use in swine. ® KIPO &amp; WIPO 2009